Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced a shift in its board’s composition, with non-executive Director Mr. Yao Fang resigning due to work reassignment, effective June 30, 2024, and Mr. Wang Kexin joining the Strategic Committee the following day. Additionally, Mr. Chen Yuqing is proposed to be appointed as a non-executive Director, pending shareholder approval at an upcoming general meeting.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
